Cognitive Impairment Detection App

A phone app that tests for signs of cognitive impairment, often attributable to Alzheimer’s disease.
A phone app that tests for signs of cognitive impairment, often attributable to Alzheimer’s disease.
ALz test is an app that detects signs of cognitive impairment as good as the Mini-Cog in 92% of all tests according to our ongoing face-to-face research. The app does not provide diagnosis, prevention, or treatment. The app tests for signs of cognitive impairment and DOESN'T diagnose any particular disease. ALz test is not a substitute for a doctor’s visit. It may help to find out if you are at risk of developing Alzheimer’s disease. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek advice of your doctor or a qualified healthcare professional regarding your medical condition. Never disregard professional medical advice or delay in seeking it when concerns arise about your health. If you would like to take a free rapid cognitive impairment test, please download it from AppStore or GooglePlay.
Our Mission: To create a phone app that detects early signs of Alzheimer’s disease.
Our Vision: A phone app for cognitive impairment testing and ongoing re-assessment.
Our Values: To help people take first steps in addressing memory and cognitive changes.
DigitalEdge https://www.digitaledge.net generously helps us with technical support!
ClinicalSelfie is a team of enthusiastic professionals:
Over a two year period we conducted 2 face-to-face research studies with groups of 65 and 61 participants. In our second research we compared the effectiveness of ALz test with the Mini-Cog*:
Objectives: To develop a digital test (ALz test) designed to detect signs of cognitive impairment as accurately as the Mini-Cog test.
Null Hypothesis: There is no statistically significant difference between passing/failing scores on the Mini-Cog and ALz tests.
Design: Case control study.
Setting: Testing was conducted at the participants’ homes, who were assessed face-to-face using the Mini-Cog and ALz tests. Mini-Cog testing involved a three-word recall and clock drawing. ALz test consisted of fifteen multiple choice picture-questions.
Participants: Volunteers who wanted to be tested (n=61) for signs of cognitive impairment.
Measurements: Rejected a null hypothesis because of the statistically significant difference detected between the Mini-Cog and ALz test scores. Calculated statistical significance of every ALz test’s question related to the correct identification of cognitive impairment in comparison to Mini-Cog. Calculated the most effective scoring criteria of the ALz test responsible for a greatest precision in detection of cognitive impairment in comparison to the Mini-Cog test and the least amount of false negative results.
Limitations: Research participants (n=61) comprised two unbalanced groups where 36 passed the Mini-Cog test and 25 failed.
Results: Two-tailed T-test rejected null hypothesis (p<0.0001) concluding that there is statistically significant difference between the Mini-Cog pass/fail and ALz test scores. Confidence interval of 95% was detected for the ALz test score at and above 69%. Correct identification of cognitive impairment in comparison to the Mini-Cog was 92% with false positive results occurring in 28% of cases.
Conclusion: Digital cognitive testing using the ALz test appears to be as effective as face-to-face assessment with the Mini-Cog evidenced by only 8% error in correct identification of cognitive impairment. Ongoing research is necessary to further confirm these findings and re-evaluate the use of this method in a more extensive face-to-face assessment.
In a nutshell: When we calculated data from the second research (n=61), there were three options to choose from for the pass/fail score (following respectively) in comparison to the Mini-Cog test:
We chose the third pass/fail score because:
* Mini-Cog is a rapid test that is used around the world by healthcare professionals to detect signs of memory impairment. We are using it in the clinical trial from a generous permission of its creator, Dr Soo Borson.
We love our customers, so feel free to send us a letter.
8600 Shore Front PKWY, #10M, Rockaway Beach, New York 11693, United States
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.